Vol. 2, No. 1, 2010
Issue release date: December 2009
Free Access
J Innate Immun 2010;2:3–16
(DOI:10.1159/000242419)
Review
Add to my selection

The Genetics of Ficolins

Garred P.a · Honoré C.a · Ma Y.J.a · Rørvig S.b · Cowland J.b · Borregaard N.b · Hummelshøj T.a
aLaboratory of Molecular Medicine, Department of Clinical Immunology, and bGranulocyte Laboratory, Department of Hematology, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
email Corresponding Author


 goto top of outline Key Words

  • Complement
  • Evolution
  • FCN1
  • FCN2
  • FCN3
  • Ficolin
  • Genetics
  • Lectin pathway

 goto top of outline Abstract

Ficolins constitute a family of proteins whose biological role has been an enigma for many years. Over the past few years it has become evident that ficolins are part of the innate immune system and function as recognition molecules in the complement system. The 3 human ficolins, ficolin-1 (M-ficolin), ficolin-2 (L-ficolin) and ficolin-3 (H-ficolin or Hakata antigen) are encoded by the FCN1, FCN2 and FCN3 genes, respectively. Phylogenetic studies suggest that ficolins are of ancient origin. Ficolin-3 seems to be the most ancient molecule, from a phylogenetic perspective. Searches in databases and phylogenetic tree analysis demonstrate that the ficolin precursor has gone through an expansion involving independent duplication events in the different branches of the evolutionary tree. Of particular interest is the prediction that ficolin-1 appears to be present as an ortholog molecule. All human FCN genes are polymorphic. The FCN2 gene encoding ficolin-2, contains polymorphisms that affect ligand binding, while differences in the serum levels are associated with promoter polymorphisms. Recently, a frame-shift variation in the FCN3 gene was described, leading to ficolin-3 deficiency and defective complement activation. This FCN3 variation was also shown to be associated with immunodeficiency. This survey summarizes the current phylogenetic and inter-individual molecular understanding of the FCN genes.

Copyright © 2009 S. Karger AG, Basel


 goto top of outline References
  1. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006;124:783–801.
  2. Shaw MH, Reimer T, Kim YG, Nunez G: NOD-like receptors (NLRs): bona fide intracellular microbial sensors. Curr Opin Immunol 2008;20:377–382.
  3. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A: Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 2008;20:538–544.
  4. Kuroki Y, Takahashi M, Nishitani C: Pulmonary collectins in innate immunity of the lung. Cell Microbiol 2007;9:1871–1879.
  5. Walport MJ: Complement. First of two parts. N Engl J Med 2001;344:1058–1066.
  6. Matsushita M, Endo Y, Fujita T: Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J Immunol 2000;164:2281–2284.
  7. Matsushita M, Kuraya M, Hamasaki N, Tsujimura M, Shiraki H, Fujita T: Activation of the lectin complement pathway by H-ficolin (Hakata antigen). J Immunol 2002;168:3502–3506.
  8. Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, Fujita T: Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol 2005;175:3150–3156.
  9. Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, Okochi K, Izuhara K, Hamasaki N: Cloning and characterization of the Hakata antigen, a member of the Ficolin/opsonin p35 lectin family. J Biol Chem 1998;273:20721–20727.
  10. Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakta M, Mizuouchi T: A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin. J Biol Chem 1996;271:2448–2454.
  11. Harumiya S, Omori A, Sugiura T, Fukumoto Y, Tachikawa H, Fujimoto D: EBP-37, a new elastin-binding protein in human plasma: structural similarity to ficolins, transforming growth factor-beta 1-binding proteins. J Biochem (Tokyo) 1995;117:1029–1035.
  12. Endo Y, Sato Y, Matsushita M, Fujita T: Cloning and characterization of the human lectin P35 gene and its related gene. Genomics 1996;36:515–521.
  13. Edgar PF: Hucolin, a new corticosteroid-binding protein from human plasma with structural similarities to ficolins, transforming growth factor-beta 1- binding proteins. FEBS Lett 1995;375:159–161.
  14. Fujimori Y, Harumiya S, Fukumoto Y, Miura Y, Yagasaki K, Tachikawa H, Fujimoto D: Molecular cloning and characterization of mouse ficolin-A. Biochem Biophys Res Commun 1998;244:796–800.
  15. Lynch NJ, Khan SU, Stover CM, Sandrini SM, Marston D, Presanis JS, Schwaeble WJ: Composition of the lectin pathway of complement in Gallus gallus: absence of mannan-binding lectin-associated serine protease-1 in birds. J Immunol 2005;174:4998– 5006.
  16. Omori-Satoh T, Yamakawa Y, Mebs D: The antihemorrhagic factor, erinacin, from the European hedgehog (Erinaceus europaeus), a metalloprotease inhibitor of large molecular size possessing ficolin/opsonin P35 lectin domains. Toxicon 2000;38:1561–1580.
  17. Kakinuma Y, Endo Y, Takahashi M, Nakata M, Matsushita M, Takenoshita S, Fujita T: Molecular cloning and characterization of novel ficolins from Xenopus laevis. Immunogenetics 2003;55:29–37.
  18. Kenjo A, Takahashi M, Matsushita M, Endo Y, Nakata M, Mizuochi T, Fujita T: Cloning and characterization of novel ficolins from the solitary ascidian, Halocynthia roretzi. J Biol Chem 2001;276:19959–19965.
  19. Teh C, Le Y, Lee SH, Lu J: M-ficolin is expressed on monocytes and is a lectin binding to N-acetyl-D-glucosamine and mediates monocyte adhesion and phagocytosis of Escherichia coli. Immunology 2000;101:225–232.
  20. Hashimoto S, Suzuki T, Dong HY, Yamazaki N, Matsushima K: Serial analysis of gene expression in human monocytes and macrophages. Blood 1999;94:837–844.
  21. Hashimoto S, Suzuki T, Dong HY, Nagai S, Yamazaki N, Matsushima K: Serial analysis of gene expression in human monocyte-derived dendritic cells. Blood 1999;94:845–852.
  22. Honore C, Rorvig S, Munthe-Fog L, Hummelshoj T, Madsen HO, Borregaard N, Garred P: The innate pattern recognition molecule ficolin-1 is secreted by monocytes/macrophages and is circulating in human plasma. Mol Immunol 2008;45:2782–2789.
  23. Frankenberger M, Schwaeble W, Ziegler-Heitbrock L: Expression of M-ficolin in human monocytes and macrophages. Mol Immunol 2007;45:1424–1430.
  24. Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, Parks RJ, Tschopp J: The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008;452:103–107.
  25. Frederiksen PD, Thiel S, Larsen CB, Jensenius JC: M-ficolin, an innate immune defence molecule, binds patterns of acetyl groups and activates complement. Scand J Immunol 2005;62:462–473.
  26. Hummelshoj T, Munthe-Fog L, Madsen HO, Sim RB, Garred P: Comparative study of the human ficolins reveals unique features of ficolin-3 (Hakata antigen). Mol Immunol 2008;45:1623–1632.
  27. Gulla KC, Gupta K, Gupta RK, Vyas V, Hajela K: Development of a fluorescence assay for the detection of L-ficolin-MASP in serum or purified samples. J Biochem Biophys Methods 2006;66:59–71.
  28. Hummelshoj T, Munthe-Fog L, Madsen HO, Fujita T, Matsushita M, Garred P: Polymorphisms in the FCN2 gene determine serum variation and function of ficolin-2. Hum Mol Genet 2005;14:1651–1658.
  29. Kilpatrick DC, Fujita T, Matsushita M: P35, an opsonic lectin of the ficolin family, in human blood from neonates, normal adults, and recurrent miscarriage patients. Immunol Lett 1999;67:109–112.
  30. Krarup A, Sorensen UB, Matsushita M, Jensenius JC, Thiel S: Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin. Infect Immun 2005;73:1052–1060.
  31. Munthe-Fog L, Hummelshoj T, Hansen BE, Koch C, Madsen HO, Skjodt K, Garred P: The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand J Immunol 2007;65:383–392.
  32. Tenner AJ: Membrane receptors for soluble defense collagens. Curr Opin Immunol 1999;11:34–41.
  33. Inaba S, Okochi K, Yae Y, Niklasson F, de Verder CH: Serological studies of an SLE-associated antigen-antibody system discovered as a precipitation reaction in agarose gel: the HAKATA antigen-antibody system. Fukuoka Igaku Zasshi 1990;81:284–291.
  34. Epstein WV, Tan M: An antibody-like material in systemic lupus erythematosus directed toward a thermolabile serum macroprotein. Arthritis Rheum 1973;16:43–51.
  35. Akaiwa M, Yae Y, Sugimoto R, Suzuki SO, Iwaki T, Izuhara K, Hamasaki N: Hakata antigen, a new member of the ficolin/opsonin p35 family, is a novel human lectin secreted into bronchus/alveolus and bile. J Histochem Cytochem 1999;47:777–785.
  36. Ohashi T, Erickson HP: The disulfide bonding pattern in ficolin multimers. J Biol Chem 2004;279:6534–6539.
  37. Matsushita M, Endo Y, Hamasaki N, Fujita T: Activation of the lectin complement pathway by ficolins. Int Immunopharmacol 2001;1:359–363.
  38. Krarup A, Thiel S, Hansen A, Fujita T, Jensenius JC: L-ficolin is a pattern recognition molecule specific for acetyl groups. J Biol Chem 2004;279:47513–47519.
  39. Lu J, Le Y: Ficolins and the fibrinogen-like domain. Immunobiology 1998;199:190–199.
  40. Matsushita M, Fujita T: Ficolins and the lectin complement pathway. Immunol Rev 2001;180:78–85.
  41. Erickson HP: Evolution of the tenascin family: implications for function of the C-terminal fibrinogen-like domain. Perspect Dev Neurobiol 1994;2:9–19.
  42. Kobayashi R, Mizutani A, Hidaka H: Isolation and characterization of a 36-kDa microfibril-associated glycoprotein by the newly synthesized isoquinolinesulfonamide affinity chromatography. Biochem Biophys Res Commun 1994;198:1262–1266.
  43. Gokudan S, Muta T, Tsuda R, Koori K, Kawahara T, Seki N, Mizunoe Y, Wai SN, Iwanaga S, Kawabata S: Horseshoe crab acetyl group-recognizing lectins involved in innate immunity are structurally related to fibrinogen. Proc Natl Acad Sci USA 1999;96:10086–10091.
  44. Garlatti V, Belloy N, Martin L, Lacroix M, Matsushita M, Endo Y, Fujita T, Fontecilla-Camps JC, Arlaud GJ, Thielens NM, Gaboriaud C: Structural insights into the innate immune recognition specificities of L- and H-ficolins. EMBO J 2007;26:623–633.
  45. Tanio M, Kondo S, Sugio S, Kohno T: Trivalent recognition unit of innate immunity system: crystal structure of trimeric human M-ficolin fibrinogen-like domain. J Biol Chem 2007;282:3889–3895.
  46. Thompson JD, Higgins DG, Gibson TJ: Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673–4680.
  47. Endo Y, Liu Y, Kanno K, Takahashi M, Matsushita M, Fujita T: Identification of the mouse H-ficolin gene as a pseudogene and orthology between mouse ficolins A/B and human L-/M-ficolins. Genomics 2004;84:737–744.
  48. Lu J, Tay PN, Kon OL, Reid KB: Human ficolin: cDNA cloning, demonstration of peripheral blood leucocytes as the major site of synthesis and assignment of the gene to chromosome 9. Biochem J 1996;313:473–478.
  49. Rorvig S, Honore C, Larsson L-I, Ohlsson S, Pedersen CC, Jacobsen LC, Cowland JB, Garred P, Borregaard N: Ficolin-1 is present in a highly mobilizable subset of human neutrophil granules and associates with the cell surface after stimulation with fMLP. J Leukoc Biol 2009, DOI:10.1189/jlb.1008606.

    External Resources

  50. Wittenborn T, Thiel S, Jensen L, Nielsen HJ, Jensenius JC: Characteristics and biological variations of M-ficolin, a pattern recognition molecule, in plasma. J Innate Immun 2009; DOI: 10.1159/000218324.

    External Resources

  51. Tsujimura M, Miyazaki T, Kojima E, Sagara Y, Shiraki H, Okochi K, Maeda Y: Serum concentration of Hakata antigen, a member of the ficolins, is linked with inhibition of Aerococcus viridans growth. Clin Chim Acta 2002;325:139–146.
  52. Munthe-Fog L, Hummelshoj T, Ma YJ, Hansen BE, Koch C, Madsen HO, Skjodt K, Garred P: Characterization of a polymorphism in the coding sequence of FCN3 resulting in a ficolin-3 (Hakata antigen) deficiency state. Mol Immunol 2008;45:2660–2666.
  53. Kuraya M, Matsushita M, Endo Y, Thiel S, Fujita T: Expression of H-ficolin/Hakata antigen, mannose-binding lectin-associated serine protease (MASP)-1 and MASP-3 by human glioma cell line T98G. Int Immunol 2003;15:109–117.
  54. Garred P: Mannose-binding lectin genetics: from A to Z. Biochem Soc Trans 2008;36:1461–1466.
  55. Worthley DL, Bardy PG, Mullighan CG: Mannose-binding lectin: biology and clinical implications. Intern Med J 2005;35:548–555.
  56. Hellemann D, Larsson A, Madsen HO, Bonde J, Jarlo JO, Wiis J, Faber T, Wetterslev J, Garred P: Heterozygosity of mannose-binding lectin (MBL2) genotypes predicts advantage (heterosis) in relation to fatal outcome in intensive care patients. Hum Mol Genet 2007;16:3071–3080.
  57. Troelsen L, Garred P, Madsen HO, Jacobsen S: Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis. Arthritis Rheum 2006;56:21–29.

    External Resources

  58. Hansen TK, Gall MA, Tarnow L, Thiel S, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A: Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med 2006;166:2007–2013.
  59. Herpers BL, Immink MM, de Jong BA, Velzen-Blad H, de Jongh BM, van Hannen EJ: Coding and non-coding polymorphisms in the lectin pathway activator L-ficolin gene in 188 Dutch blood bank donors. Mol Immunol 2006;43:851–855.
  60. Hummelshoj T, Munthe-Fog L, Madsen HO, Garred P: Functional SNPs in the human ficolin (FCN) genes reveal distinct geographical patterns. Mol Immunol 2008;45:2508–2520.
  61. Vander CB, Nuytinck L, Boullart L, Elewaut D, Waegeman W, Van TM, De ME, Lebeer K, Rossau R, De KF: Polymorphisms in the ficolin 1 gene (FCN1) are associated with susceptibility to the development of rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1792–1795.
  62. Schlapbach LJ, Kessler U, Thiel S, Hansen AG, Nelle M, Ammann RA, Aebi C, Jensenius JC: M-ficolin in the neonatal period: Associations with need for mechanical ventilation and mortality in premature infants with necrotising enterocolitis. Mol Immunol 2009;46:2597–2603.
  63. Cedzynski M, Nuytinck L, Atkinson AP, St Swierzko A, Zeman K, Szemraj J, Szala A, Turner ML, Kilpatrick DC: Extremes of L-ficolin concentration in children with recurrent infections are associated with single nucleotide polymorphisms in the FCN2 gene. Clin Exp Immunol 2007;150:99–104.
  64. Chen X, Katoh Y, Nakamura K, Oyama N, Kaneko F, Endo Y, Fujita T, Nishida T, Mizuki N: Single nucleotide polymorphisms of ficolin 2 gene in Behcet’s disease. J Dermatol Sci 2006;43:201–205.
  65. Chapman SJ, Vannberg FO, Khor CC, Segal S, Moore CE, Knox K, Day NP, Davies RJ, Crook DW, Hill AV: Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease. Mol Immunol 2007;44:3267–3270.
  66. de Messias-Reason I, Kremsner PG, Kun JF: Functional haplotypes that produce normal ficolin-2 levels protect against clinical leprosy. J Infect Dis 2009;199:801–804.
  67. Ma YJ, Doni A, Hummelshoj T, Honore C, Bastone A, Mantovani A, Thielens NM, Garred P: Synergy between ficolin-2 and PTX3 boost innate immune recognition and complement deposition. J Biol Chem 2009; DOI: 10.1074/jbc.M109.009225.

    External Resources

  68. Ruskamp JM, Hoekstra MO, Postma DS, Kerkhof M, Bottema RW, Koppelman GH, Rovers MM, Wijga AH, de Jongste JC, Brunekreef B, Sanders EA: Exploring the role of polymorphisms in ficolin genes in respiratory tract infections in children. Clin Exp Immunol 2009;155:433–440.
  69. de Messias-Reason I, Schafranski MD, Kremsner PG, Kun JFJ: Ficolin-2 (FCN2) functional polymorphisms and the risk of rheumatic fever and rheumatic heart disease. Clin Exp Immunol 2009;157:395–399.
  70. Munthe-Fog L, Hummelshoj T, Honore C, Madsen HO, Permin H, Garred P: Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N Engl J Med 2009;360:2637–2644.
  71. Honore C, Hummelshoj T, Hansen BE, Madsen HO, Eggleton P, Garred P: The innate immune component ficolin 3 (Hakata antigen) mediates the clearance of late apoptotic cells. Arthritis Rheum 2007;56:1598–1607.
  72. Wang CC, Yim KW, Poon TC, Choy KW, Chu CY, Lui WT, Lau TK, Rogers MS, Leung TN: Innate immune response by ficolin binding in apoptotic placenta is associated with the clinical syndrome of preeclampsia. Clin Chem 2007;53:42–52.
  73. Schlapbach LJ, Aebi C, Hansen AG, Hirt A, Jensenius JC, Ammann RA: H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients. Clin Exp Immunol 2009;157:83–89.

 goto top of outline Author Contacts

Prof. Dr. Peter Garred
Laboratory of Molecular Medicine, Department of Clinical Immunology
Sect. 7631, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen
Blegdamsvej 9, DK–2100 Copenhagen (Denmark)
Tel. +45 3545 7631, Fax +45 3545 8766, E-Mail garred@post5.tele.dk


 goto top of outline Article Information

Received: July 13, 2009
Accepted after revision: August 18, 2009
Published online: September 24, 2009
Number of Print Pages : 14
Number of Figures : 6, Number of Tables : 3, Number of References : 73


 goto top of outline Publication Details

Journal of Innate Immunity

Vol. 2, No. 1, Year 2010 (Cover Date: December 2009)

Journal Editor: Herwald H. (Lund), Egesten A. (Lund)
ISSN: 1662-811X (Print), eISSN: 1662-8128 (Online)

For additional information: http://www.karger.com/JIN


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.